Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model ; volume:41 ; number:2 ; day:17 ; month:2 ; year:2024 ; pages:91-102 ; date:4.2024
Clinical & experimental metastasis ; 41, Heft 2 (17.2.2024), 91-102, 4.2024

Creator
Pourjamal, Negar
Yazdi, Narjes
Halme, Aleksi
Joncour, Vadim Le
Laakkonen, Pirjo
Saharinen, Pipsa
Joensuu, Heikki
Barok, Mark
Contributor
SpringerLink (Online service)

DOI
10.1007/s10585-024-10278-2
URN
urn:nbn:de:101:1-2406130846241.297867816428
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Pourjamal, Negar
  • Yazdi, Narjes
  • Halme, Aleksi
  • Joncour, Vadim Le
  • Laakkonen, Pirjo
  • Saharinen, Pipsa
  • Joensuu, Heikki
  • Barok, Mark
  • SpringerLink (Online service)

Other Objects (12)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients

HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer

Related objects